A word from the CEO
“AroCell began 2023 with a strong first quarter, building on the positive momentum of 2022. We are experiencing significant and consistent sales growth in our two primary market categories, oncology and bacteriology. In addition, we are beginning to see results from clinical studies, as well as new collaborations with strategic partners. During the quarter, we also made significant progress toward putting our biomarkers on automated CLIA platforms.”

Anders Hultman, CEO

Reporting period January 1st – March 31st

• Net sales amounted to KSEK 11,053 (7,770).
• Profit after financial items amounted to KSEK -13,668 (-15,695)*.
• Cash flow from operating activities for the period amounted to KSEK -4,522 (-8,120).
• Earnings per share before and after dilution amounted to SEK -0.06 (-0.09).
• Cash and cash equivalents at the end of the period amounted to KSEK 59,956 (90,870).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.

Events during the period January 1st – March 31st

• A new agreement has been signed with ZECEN Biotech for the automation of another one of the company’s tumor markers, UBC®, on ZECEN Biotech’s automated platforms.

• AroCell is expanding its sales and distribution network in Africa by signing a distributor agreement with Sub-Saharan Biomedical P.L.C. for the sale of TUBEX® TF in Ethiopia.

• A study has been published in the peer-reviewed journal “Cancers” showing that the use of AroCell TK 210 ELISA in combination with traditional biomarkers CA 125 and HE4 can significantly improve sensitivity and outperform the ROMA index in early detection of ovarian cancer. The study, titled “A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer” was conducted in collaboration with the University Medical Centre Ljubljana, Slovenia.

• An expert-reviewed article on thymidine kinase 1 (TK1) has been published in the scientific journal International Journal of Molecular Sciences. The study, titled “Prediction of overall survival by thymidine kinase 1 combined with prostate specific antigen in men with prostate cancer” was conducted by a research group at Karolinska Institutet and Karolinska University Hospital. It showed that the combination of TK1 and PSA provides a new biomarker that can indicate survival length in prostate cancer patients at an early stage.

Events after the period
No significant events have occurred after the end of the period. 

Interim report January 1st – March 31st, 2023 (Link)